|
|
Article: HGS/TIGR Funding Relationship Reaches Early Conclusion
- Article from:
- PR Newswire
- Article date:
- June 23, 1997
CopyrightCOPYRIGHT 1997 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ROCKVILLE, Md., June 23 /PRNewswire/ -- Human Genome Sciences, Inc. (HGS) (Nasdaq: HGSI) and The Institute for Genomic Research (TIGR) today announced that they have signed an agreement whereby HGS will cease future payments to TIGR in return for relinquishing rights to future work done by TIGR. While this ends the HGS/TIGR relationship, HGS will retain all rights to patents granted now or in the future on work by TIGR prior to this agreement. Additionally, TIGR agrees not to enter into commercial agreements for the next four years on selected therapeutic proteins (proteins used as drugs) and associated diagnostic tests in development by HGS. Furthermore, TIGR agrees ...
Related newspaper, magazine, and journal articles:
|
|
Article: Cambridge Antibody Technology and Human Genome ...
PR Newswire;
January 8, 2002 ;
700+ words
... ... Cambridge Antibody Technology and Human Genome Sciences, Inc. today announce that Human Genome Sciences has exercised an option to enter into ... evaluated as an anti-cancer drug by Human Genome Sciences. TRAIL Receptor 1, which was discovered ...
|
|